oncology

News in brief: Intravenous Herceptin not available on PBS after October 2021; COVID-19 vax booster needed for some patients; Antivax practitioners will be struck off, AHPRA warns

Intravenous Herceptin not available after October 2021, Intravenous Herceptin will no longer be available on the PBS from 1 October, but biosimilar alternatives will be reimbursed for women with HER-2 positive breast cancer, according to the Breast Cancer Network Australia. BCNA is advising women that the biosimilar alternatives to Roche’s IV Herceptin approved in Australia ...

Already a member?

Login to keep reading.


OR
© 2022 the limbic